Based on the Avicanna Inc stock forecast from 0 analysts, the average analyst target price for Avicanna Inc is not available over the next 12 months. Avicanna Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Avicanna Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Avicanna Inc’s stock price was CAD 0.34. Avicanna Inc’s stock price has changed by +3.03% over the past week, -8.11% over the past month and +0.00% over the last year.
No recent analyst target price found for Avicanna Inc
No recent average analyst rating found for Avicanna Inc
Company Overview Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada. Read Less
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes appro...Read More
Frequently Asked Questions About Avicanna Inc (AVCN:CA) Stock
Stock Target Advisor's fundamental analysis for Avicanna Inc's stock is Bearish.
Unfortunately we do not have enough data on AVCN:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AVCN:CA's stock to indicate what its average analyst target is.
AVCN:CA stock's Price/Earning ratio is -99,999.99.
Our analysis grades AVCN:CA stock's Price / Earning ratio at A. This means that AVCN:CA stock's Price/Earning ratio is above 6.999999999999995% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSX exchange.
Based on this AVCN:CA may be undervalued for its sector.
The last closing price of AVCN:CA's stock was CAD 0.34.
The most recent market capitalization for AVCN:CA is CAD 0.03B.
Unfortunately we do not have enough analyst data on AVCN:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Avicanna Inc's stock.
As per our most recent records Avicanna Inc has 87 Employees.
Avicanna Inc's registered address is 480 University Avenue, Toronto, ON, Canada, M5G 1V2.
You can get more information about it from Avicanna Inc's website at https://www.avicanna.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Frequently Asked Questions About Avicanna Inc (AVCN:CA) Stock
Stock Target Advisor's fundamental analysis for Avicanna Inc's stock is Bearish.
Unfortunately we do not have enough data on AVCN:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AVCN:CA's stock to indicate what its average analyst target is.
AVCN:CA stock's Price/Earning ratio is -99,999.99.
Our analysis grades AVCN:CA stock's Price / Earning ratio at A. This means that AVCN:CA stock's Price/Earning ratio is above 6.999999999999995% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSX exchange.
Based on this AVCN:CA may be undervalued for its sector.
The last closing price of AVCN:CA's stock was CAD 0.34.
The most recent market capitalization for AVCN:CA is CAD 0.03B.
Unfortunately we do not have enough analyst data on AVCN:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Avicanna Inc's stock.
As per our most recent records Avicanna Inc has 87 Employees.
Avicanna Inc's registered address is 480 University Avenue, Toronto, ON, Canada, M5G 1V2.
You can get more information about it from Avicanna Inc's website at https://www.avicanna.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AVCN:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
